Healthcare | April 07, 2025
Fexuprazan has the longest half-life of 9 hours among potassium-competitive acid blockers
The portfolio includes branded injectable cephalosporines for infectious diseases
The company expects to launch this product through its marketing partner in the near future
The IND application supports the next phase of development of SBO-154
Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone
Approval brings AstraZeneca and Daiichi Sankyo’s Enhertu earlier in the treatment of HR-positive, HER2-low breast cancer and broadens the eligible patient population to those with HER2-ultralow disease
PRX-PLUS has a unique product feature with its deep-impacting formula
The consignment of USFDA qualified Metformin (1000mg) was received by the province of Mendoza for distribution in the public health system
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
Subscribe To Our Newsletter & Stay Updated
